Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they controlEmanuele de Rinaldis, Andrew Tutt, Patrycja Gazińska et al.|BMC Genomics|2013Cited by 87
Data from DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin LymphomaDongwei Li, Andrew G. Polson, Kirsten Achilles Poon et al.|Unknown|2023Cited by 0
Supplementary Figure 1 from DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin LymphomaDongwei Li, Andrew G. Polson, Kirsten Achilles Poon et al.|Unknown|2023Cited by 0
Supplementary Table 1 from DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin LymphomaDongwei Li, Andrew G. Polson, Kirsten Achilles Poon et al.|Unknown|2023Cited by 0
Supplementary Table 1 from DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin LymphomaDongwei Li, Andrew G. Polson, Kirsten Achilles Poon et al.|Unknown|2023Cited by 0